Cullinan Therapeutics Shares Preclinical Data for CLN-978
Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company, presented new preclinical data for CLN-978 at the American College of Rheumatology (ACR) Convergence 2025.
CLN-978, a novel investigational CD19xCD3 bispecific T cell engager, led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases.
- Presented at ACR Convergence 2025 in Chicago, Illinois, October 24-29
- Poster presentation session on October 28, 10:30 a.m.-12:30 p.m. CT (Poster Session C, Poster Number 2293)
- Cullinan Therapeutics will also have a Booth (#1074) in the Exhibit Hall
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases
Author summary: Cullinan Therapeutics presents preclinical data for CLN-978.
More News
- ICYMI: AAO 2025 showcases new technologies and continued research | Ophthalmology Times - Clinical Insights for Eye Specialists
- West Indies ease past Bangladesh in first T20I
- Key Asks from Government – As Staffordshire Finalises LGR Submission - Staffordshire County Council Newsroom
- BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia
- Wallingford deli asks for help to keep feeding people in need
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Biopic reintroduces female revolutionary hero - BusinessWorld Online
- The environmental impact of the 2026 World Cup
- Philippines economy to grow 5.6% in 2025 – Fitch